Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Cash & Current Investments: 2011-2025

Historic Cash & Current Investments for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to $21.9 million.

  • Fennec Pharmaceuticals' Cash & Current Investments fell 45.57% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.0 million, marking a year-over-year decrease of 39.14%. This contributed to the annual value of $26.6 million for FY2024, which is 100.72% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Cash & Current Investments stood at $21.9 million, which was up 17.33% from $18.7 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Cash & Current Investments' 5-year high stood at $51.2 million during Q1 2024, with a 5-year trough of $12.4 million in Q3 2023.
  • Moreover, its 3-year median value for Cash & Current Investments was $21.9 million (2025), whereas its average is $25.3 million.
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Cash & Current Investments plummeted by 58.33% in 2023, and later skyrocketed by 285.74% in 2024.
  • Quarterly analysis of 5 years shows Fennec Pharmaceuticals' Cash & Current Investments stood at $24.3 million in 2021, then climbed by 22.26% to $23.8 million in 2022, then crashed by 44.19% to $13.3 million in 2023, then skyrocketed by 100.72% to $26.6 million in 2024, then plummeted by 45.57% to $21.9 million in 2025.
  • Its Cash & Current Investments stands at $21.9 million for Q3 2025, versus $18.7 million for Q2 2025 and $22.7 million for Q1 2025.